|
gptkbp:instanceOf
|
biotechnology company
|
|
gptkbp:acquisition
|
gptkb:Calithera_Biosciences
gptkb:MediGene_AG
|
|
gptkbp:CEO
|
gptkb:Hervé_Hoppenot
|
|
gptkbp:clinicalTrials
|
Phase 1
Phase 2
Phase 3
multiple ongoing
|
|
gptkbp:collaborations
|
gptkb:AstraZeneca
gptkb:Bristol-Myers_Squibb
gptkb:Pfizer
gptkb:Merck_&_Co.
|
|
gptkbp:employees
|
~1,500
|
|
gptkbp:focus
|
cancer treatment
inflammation treatment
|
|
gptkbp:founded
|
1991
|
|
gptkbp:founder
|
gptkb:Paul_Friedman
|
|
gptkbp:headCoach
|
increased since 2010
|
|
gptkbp:headquarters
|
gptkb:Wilmington,_Delaware
gptkb:Wilmington,_Delaware,_USA
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Incyte Corporation
|
|
gptkbp:market
|
~$20 billion (2021)
|
|
gptkbp:partnerships
|
gptkb:Takeda_Pharmaceutical_Company
gptkb:Mylan
gptkb:Boehringer_Ingelheim
gptkb:Roche
gptkb:Amgen
gptkb:Gilead_Sciences
gptkb:Eli_Lilly_and_Company
Novartis
Sanofi
AbbVie
|
|
gptkbp:patentType
|
Iclusig (2012)
Monjuvi (2020)
Pemigatinib (2020)
Jakafi_(2011)
|
|
gptkbp:products
|
Jakafi
Iclusig
Pemigatinib
Monjuvi
|
|
gptkbp:researchFocus
|
oncology
autoimmune diseases
hematology
|
|
gptkbp:revenue
|
$1.1 billion (2020)
|
|
gptkbp:stockSymbol
|
gptkb:INCY
|
|
gptkbp:subsidiary
|
Incyte Biosciences International Sàrl
Incyte Europe Sàrl
Incyte_Pharmaceuticals,_Inc.
Incyte_Research_Institute
|
|
gptkbp:tradedOn
|
gptkb:NASDAQ
|
|
gptkbp:website
|
www.incyte.com
|